A new study in The Journal of Nuclear Medicine reports that a noninvasive DNA blood test can help select advanced prostate cancer patients most likely to benefit from 223Ra radiopharmaceutical therapy and monitor treatment response.
Tempus has launched the ArteraAI Prostate Test, a CLIA-certified, CAP-accredited AI tool for metastatic hormone-sensitive prostate cancer, offering personalized risk estimates and designed to support treatment decisions, according to the company.
A genomic test widely used in prostate cancer care can more accurately identify which men with early-stage disease face high risk of recurrence after treatment.
Phase 3 STAMPEDE trial data demonstrates Decipher Prostate test can predict docetaxel treatment benefit, potentially helping patients avoid unnecessary toxicity.
Read More
The risk stratification tool is designed to predict long-term outcomes for patients with non-metastatic prostate cancer.
Read More
Fellow Health showcased innovative research, emphasizing mail-in semen testing to enhance prostate cancer diagnostics and PVSA care.
Read More
Veracyte has launched Decipher Prostate test, a Medicare-covered test for guiding treatment in metastatic prostate cancer.
Read More
A new study confirms Cleveland Diagnostics’ IsoPSA test effectively differentiates between low- and high-risk prostate cancer patients.
Read More
Decipher Prostate Genomic Classifier data is included in a new SEER Program database, enabling the study of prostate cancer outcomes.
Read More
Lynx Dx announced at-home availability of a urine-based prostate cancer test that eliminates the need for a digital rectal exam.
Read More
A new study validated a urine test that offers a less invasive, more accurate alternative to traditional prostate cancer screening.
Read More
A review found gaps remain for genomic classifier tests for their cost-effectiveness, clinical utility, and impact on diverse populations.
Read More
The AR-ctDETECT test identifies circulating tumor DNA in advanced prostate cancer patients, providing critical insights for prognostication.
Read More
A genetic variant in the PSA gene may help improve prostate cancer diagnostics by distinguishing between aggressive and non-aggressive types.
Read More
A study shows that measuring CTCs at the time of metastatic prostate cancer diagnosis can predict survival and guide treatment decisions.
Read More
A new prostate cancer screening method could help better predict which patients need to undergo a biopsy, reducing unnecessary procedures.
Read More
GRAIL’s Galleri multi-cancer early detection test demonstrates strong performance in preferentially identifying aggressive prostate cancers.
Read More
A newly discovered class of RNA molecules in extracellular vesicles could serve as biomarkers for non-invasive cancer diagnosis.
Read More